Some Future Directions in Medical Genetics  by Motulsky, Arno G.
Am. J. Hum. Genet. 66:1190–1191, 2000
1190
1999 ASHG AWARD FOR EXCELLENCE IN EDUCATION
Some Future Directions in Medical Genetics
Arno G. Motulsky
Working in human and medical genetics in the last half
of the 20th century has been a privilege. Our field has
evolved from Cinderella status to become the queen of
the biomedical sciences. The honor of receiving the “Ex-
cellence in Education” award of the American Society
of Human Genetics is therefore particularly gratifying.
I thank my many colleagues, postdoctoral fellows, and
collaborators who have made my work possible. Par-
ticularly, I call attention to Friedrich Vogel’s major role
in writing our book on human genetics.
Pathogenesis of Genetic Disease
As medical geneticists, we can contribute to an under-
standing of the pathogenic mechanisms of genetically
influenced disease. The public supports such research in
the hope of prevention and treatment. Where will the
desired answers come from? In monogenic diseases, po-
sitional cloning has identified various mutations in many
different genes. Often, we know how a mutant gene
product causes disease, such as in the various enzyme
deficiencies and protein defects. In an increasing number
of examples, however, the gene products identified by
positional cloning are completely novel.We do not know
their function, and we have few or no clues how a mu-
tant gene causes disease. Examples are Huntington dis-
ease, Friedreich ataxia, Werner syndrome, and many
others. How does an abnormal helicase produce findings
suggestive of premature aging, as in Werner syndrome?
We need to learn much more about the mechanisms of
pathogenesis, i.e., the pathways that lead from the al-
tered gene to the phenotype. Many monogenic diseases,
despite identical nucleotide errors in the same gene, such
as in adult Gaucher disease, exhibit low penetrance, but
the responsible mechanism remains unknown.
One approach needing more attention is the study of
modifying genes. A definite example of genetic modi-
fication is the apolipoprotein E polymorphism that al-
ters the expression of late-onset Alzheimer disease. E4
heterozygotes and, particularly, E4 homozygotes have a
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higher risk of being affected with Alzheimer disease.
Another example is a small deletion in the CCR5 co-
receptor for the HIV virus that completely protects
against HIV infection when homozygous and increases
the time period betweenHIV infection and clinical AIDS
in heterozygotes. The exciting vista of these examples
is that understanding of the mechanisms of action of
such modifiers may provide clues towards preventive or
therapeutic measures. Thus, once it is understood that
the HIV virus requires the CCR5 receptor to be infec-
tive, therapeutic and preventive agents can be devised
that use this knowledge.
Search for modifying genes also applies to the path-
ogenesis of the various complex diseases where multiple
genes are operative. So far, genomic mapping studies in
these conditions have often given nonreproducible re-
sults. Excepting the uncommon monogenic subtypes,
few, if any, genes or gene products have been definitely
identified by this approach alone. Markers such as the
common single-nucleotide polymorphisms (SNPs) that
are in linkage disequilibrium with a disease locus may
lead to disease-gene identification, and extensive efforts
are underway to identify SNPs in various complex dis-
eases as well as in traits of pharmacogenomic interest.
The term “phenogenetics” has been used to denote the
genetic study of phenotypic expression and may be use-
ful to call attention to studies on modifying genes.
However, identification of the involved genes will not
be enough. We need more attention to gene-gene inter-
action, to epistatic factors, and to definition of the spe-
cific environmental factors in gene-environmental in-
teraction. The role of developmental changes at the
embryonic-fetal level needs attention. For late-onset dis-
eases, the mechanisms of the aging in different organs
and its role in pathogenesis of disease requires better
understanding.
Stochastic or random factors may play a role in dis-
ease pathogenesis. Why is concordance for complex dis-
ease in identical twins often only in the 40%–70%
range, even though such twins share all of their germinal
genes and usually have the same intrauterine and post-
natal environment. Do somatic mutations play a role?
Is the frequent lack of MZ-twin concordance really en-
vironmental? Are there other poorly understood epi-
genetic factors? Does chance ever play a role, particu-
larly during development?
The term “phenomics” has been used to denote the
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broad study of the phenotype that must be carried out
in conjunction with genomics. “Proteomics,” i.e., study
of proteins and their expression during developmental,
physiologic, and pathologic processes using many new
techniques, is an important part of phenomics.
Many scientific approaches are required to under-
stand the pathway from genotype to phenotype. Fields
of genetics that are involved include molecular genetics,
biochemical genetics, pharmacogenetics, clinical genet-
ics, genetics of aging, and statistical and epidemiologic
genetics. We will need the help of specialists in many
areas. Biochemists, cellular and system physiologists,
pathologists, and pharmacologists will need to provide
data and insights. There is need for broadly trained
individuals in medical genetics who, by using a variety
of current information from various computerized da-
tabases, can make sense of the large amounts of emerg-
ing data. Nick Schork suggested that we need a new
kind of researcher—an “armchair” scientist who can
excel in this activity. However, skill in informatics will
not be enough. We need creative minds that are able to
integrate the many data into meaningful patterns to
suggest promising new studies to understand disease.
Broadly trained medical geneticists are ideal candidates
for these activities.
Implications for Training in Medical Genetics
Renewed attention to biochemistry and physiology will
be important, so that team work will be easier. Study of
modifying genes in simpler organisms such as mice and
fruit flies will be useful. Laboratory workers need to
learn about the principles of statistics, population ge-
netics, and epidemiology to appreciate the power and
limitations of quantitative approaches. Quantitatively
trained geneticists will need exposure to the biologic re-
alities posed by the problems they work on.
Clinical investigators and physician-scientists who
work on problems of genetically influenced disease are
either medical geneticists or work with geneticists. In-
termediate phenotypes (i.e., those phenotypes that are
closer to gene action than the diagnostic label of the
disease) often need to be identified. As an example, the
study of hyperlipidemia, instead of coronary artery dis-
ease, has been useful in starting to dissect the genetic
etiology of arteriosclerosis. Since large numbers of pa-
tients and normal controls are often required for as-
sociation studies (such as with SNPs), the logistical ar-
rangements and problems of working in a consortium
with large numbers of patients in different institutions
will need to be part of training young investigators.
Ph.D. scientists in addition to in depth research require
broader training as a basis for work in disease research.
Summer courses in medical and clinical genetics specif-
ically directed at Ph.D. geneticists are a possible
solution.
Public Health Genetics
A new area of genetic education is appearing. An in-
creasing number of schools of public health are initiating
programs of public health genetics. At the University of
Washington, the program is established within the
framework of law, ethics, and public policy to emphasize
its concern for the ethical, legal, and social aspects of
human genetics. The program trains—usually at the
Master’s level, at this point, and aiming at Ph.D. pro-
grams later—professionals to work in public health de-
partments, screening programs, government and legis-
lative agencies of various sorts, policy analysis, law,
bioethics, and, to some extent, as genetic counselors,
public health nurses, and genetic epidemiologists.
The institution of these programs raises a variety of
questions. For instance, how do we educate students
without a scientific background in the science of ge-
netics? This is difficult and needs experimentation.
Public health genetics programs hopefully will pro-
vide a site for scholarly research in the ethical, legal,
and social problems of genetics. This aspect has intense
public interest. Public health genetics programs are an
ideal place where difficult problems could be researched
in a university environment in collaboration with var-
ious social science and other departments. Such work,
hopefully, will provide empirical data of various sorts.
U.S. Health Care System and Medical Genetics
The future organization of our complex health care sys-
tem and its regulation will be an important factor in
personnel requirements in medical genetics. There are
many problems. Over 40 million people are uninsured.
How can we provide appropriate genetic services to this
underserved population, and how should that be done?
Health maintenance organizations (HMOs) are here to
stay for some time. To reduce costs, these organizations
utilize cost-effectiveness analysis to define the needs for
genetic services. A likely outcome is increasing utilization
of genetic counselors, rather than of medical geneticists
in HMO settings, which is already happening in cancer
genetics. There is likely to be more patient education in
matters of genetics with attention to prevention—a wel-
come development. The specific organization of various
genetic services and the role of genetics in medical care
is difficult to predict at this time and will depend on
scientific developments and how health care in the U.S.A.
will be administered in the future. There is no question,
however, that our field of science and practice will play
an important role in the medicine of the future.
